Valproic acid as a radio-sensitizer in glioma: A systematic review and meta-analysis.
Jessica K SullivanPaul P FaheyKinglsey E AghoSimon P HurleyZhihui FengRichard O DayDavid LimPublished in: Neuro-oncology practice (2022)
This review suggests that glioma patients undergoing RT may experience prolonged survival due to HDACi VPA administration. Further randomized controlled trials are required to validate these findings. Additionally, more research into the use of HDACi radio-adjuvant treatment in non-glioma solid organ malignancies is warranted.